Abcb5(+) stem cells for treating ocular disease
US-2015374756-A1 · Dec 31, 2015 · US
Modalities for the treatment of degenerative diseases of the retina
US9562217B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9562217-B2 |
| Application number | US-201313858354-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 8, 2013 |
| Priority date | Jan 23, 2004 |
| Publication date | Feb 7, 2017 |
| Grant date | Feb 7, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
First claim
Opening claim text (preview).
We claim: 1. A composition comprising isolated human RPE cells obtained by in vitro differentiation of human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-81, wherein said human RPE cells express RPE65 and bestrophin and wherein said composition is suitable for transplantation or injection into a human patient in need thereof. 2. A composition of claim 1 wherein the human RPE cells are present in a monolayer. 3. A frozen preparation of human RPE cells obtained by in vitro differentiation of human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-81, which frozen human RPE cells upon thawing are suitable for use in treating a human patient. 4. The composition or preparation of claim 1 or 3 , wherein said human RPE cells express CRALBP, PEDF, RPE65 and bestrophin. 5. The composition or preparation of claim 1 or 3 , which comprises human RPE cells that exhibit a cobblestone, epithelial-like, polygonal appearance. 6. The composition or preparation of claim 1 or 3 , which comprises human RPE cells that express CRALBP, PEDF, RPE65 and bestrophin and exhibit a cobblestone, epithelial-like, polygonal appearance.
Assignees
Inventors
Classifications
Anti-Parkinson drugs · CPC title
Antiglaucoma agents or miotics · CPC title
Ophthalmic agents · CPC title
Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title
Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9562217B2 cover?
- This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
- Who is the assignee on this patent?
- Advanced Cell Tech Inc, Astellas Inst For Regenerative Medicine
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0621. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).